1. Changing the IBD Paradigm

2. Agenda

3. Current Unmet Needs in IBD (CD and UC)

4. Most Patients Will Require Surgery and Recurrence Is Likely

5. UC Results in Significant Disruption of People’s Lives

6. Economic Consequences of IBD: Indirect Costs

7. Pathophysiology and Clinical Features of the Disease

8. IBD Pathogenesis Is Complicated but Presents Multiple Potential Targets for Treatment

9. UC Has Long-Term Complications

10. CD Has Long-Term Complications

11. UC and CD Treatment: Similarities and Differences

12. Disease Assessment and Treatment Goals

13. Disease Assessment

14. Disease Assessment

15. A Lack of Symptoms Doesn’t Necessarily Reflect a Lack of Disease Activity

16. Treatment Goals Have Evolved in IBD

17. Rationale and Current Evidence for Early Treatment With Biologics

18. If IBD is Progressive, a Window of Opportunity May Exist

19. Start Anti-TNFs Early in Appropriate Patients: Anti-TNF Therapy Is Most Effective in Early Disease

20. Step-Up, Top-Down: Early Aggressive Therapy Causes Mucosal Healing in CD

21. Vedolizumab Is More Effective in Patients With CD Not Exposed to Anti-TNF

22. Ustekinumab is More Effective in an Anti-TNF Naïve Population

23. Treating to Target Is an Attractive Concept but Not Routinely Practiced

24. Treating to Target: Possible Benefits and Risks

25. REACT: Therapeutic Algorithm for CD

26. REACT: Outcomes Hospitalization, Surgery, Complication

27. Ustekinumab Induces Mucosal Improvement as Early as Week 8

28. Vedolizumab Mucosal Response in CD: US VICTORY Data

29. Short- to Medium-Term Mucosal Healing With Biologics in UC

30. Long-Term Mucosal Healing With Vedolizumab in CD and UC

31. What More Do We Need to Know?

32. Could Treating to Target Be Cost Effective?

33. Step-Up, Top-Down: Cost of Care, Years 3 and 4

34. Considerations

35. Future Directions in the Treatment of IBD

36. Personalized Drug Therapy

37. New Mechanisms of Action

38. Summary

39. Abbreviations